News | February 04, 2026
Wanbury achieves first sales invoicing and commercial shipment milestone
This achievement validates global demand and catapults Wanbury into high-growth acceleration
This achievement validates global demand and catapults Wanbury into high-growth acceleration
The Tanuku facility will focus on the production of key therapeutic APIs, including Anti-Tussive, Anti-Coagulant (Blood Thinner), Anaesthetic, and Antidepressant molecules
The company has posted net profit of Rs. 30.53 crores for the Financial Year ended March 31, 2025
The inspection conducted from December 16, 2024 to December 20, 2024 by the Brazil Health Regulatory Agency (ANVISA)
The implementation, spearheaded by Deloitte Consulting, brings together domain expertise and cutting-edge technology
Revenue from operations also dropped 8.3 per cent at Rs. 133.5 crore in Q3 FY25
The company will receive GMP compliance certificate which will further help to accelerate the business growth across the globe
EBITDA for the quarter is Rs. 21.6 crore as against Rs. 18.1 crore in Q2 FY24
Wanbury receives CEP approval from EDQM for launch of Dextromethorphan API
USFDA has determined that the inspection classification of this facility is "No Action Indicated" (NAI) with zero 483 observation
Subscribe To Our Newsletter & Stay Updated
